220 related articles for article (PubMed ID: 27389279)
1. Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier.
Garcia PV; Seiva FR; Carniato AP; de Mello Júnior W; Duran N; Macedo AM; de Oliveira AG; Romih R; Nunes Ida S; Nunes Oda S; Fávaro WJ
BMC Cancer; 2016 Jul; 16():422. PubMed ID: 27389279
[TBL] [Abstract][Full Text] [Related]
2. Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model.
Fávaro WJ; Socca EAR; Böckelmann PK; Reis IB; Garcia PV; Durán N
Med Oncol; 2022 Jan; 39(2):24. PubMed ID: 34982270
[TBL] [Abstract][Full Text] [Related]
3. Alterations in ubiquitin ligase Siah-2 and its corepressor N-CoR after P-MAPA immunotherapy and anti-androgen therapy: new therapeutic opportunities for non-muscle invasive bladder cancer.
Garcia PV; Apolinário LM; Böckelmann PK; da Silva Nunes I; Duran N; Fávaro WJ
Int J Clin Exp Pathol; 2015; 8(5):4427-43. PubMed ID: 26191134
[TBL] [Abstract][Full Text] [Related]
4. Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with p - mapa and systemic administration of cisplatin and doxorubicin.
Dias QC; Nunes ID; Garcia PV; Favaro WJ
Int Braz J Urol; 2016; 42(5):942-954. PubMed ID: 24893914
[TBL] [Abstract][Full Text] [Related]
5. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract][Full Text] [Related]
6. OncoTherad® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway.
Reis IB; Tibo LHS; Socca EAR; de Souza BR; Durán N; Fávaro WJ
Tissue Cell; 2022 Jun; 76():101762. PubMed ID: 35245856
[TBL] [Abstract][Full Text] [Related]
7. Intravesical Immunomodulatory Imiquimod Enhances Bacillus Calmette-Guérin Downregulation of Nonmuscle-invasive Bladder Cancer.
Camargo JA; Passos GR; Ferrari KL; Billis A; Saad MJA; Reis LO
Clin Genitourin Cancer; 2018 Jun; 16(3):e587-e593. PubMed ID: 29174504
[TBL] [Abstract][Full Text] [Related]
8. OncoTherad
Alonso JCC; de Souza BR; Reis IB; de Arruda Camargo GC; de Oliveira G; de Barros Frazão Salmazo MI; Gonçalves JM; de Castro Roston JR; Caria PHF; da Silva Santos A; de Freitas LLL; Billis A; Durán N; Fávaro WJ
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139364
[TBL] [Abstract][Full Text] [Related]
9. Effects of intravesical therapy with platelet-rich plasma (PRP) and Bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer.
Dias LP; Luzo ÂCM; Volpe BB; Durán M; Galdames SEM; Ferreira LAB; Durán N; Fávaro WJ
Tissue Cell; 2018 Jun; 52():17-27. PubMed ID: 29857824
[TBL] [Abstract][Full Text] [Related]
10. Systemic versus localized Bacillus Calmette Guérin immunotherapy of bladder cancer promotes an anti-tumoral microenvironment: Novel role of trained immunity.
Atallah A; Grossman A; Nauman RW; Paré JF; Khan A; Siemens DR; Cotechini T; Graham CH
Int J Cancer; 2024 Jul; 155(2):352-364. PubMed ID: 38483404
[TBL] [Abstract][Full Text] [Related]
11. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
Grabe-Heyne K; Henne C; Odeyemi I; Pöhlmann J; Ahmed W; Pollock RF
J Med Econ; 2023; 26(1):411-421. PubMed ID: 36897006
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
[TBL] [Abstract][Full Text] [Related]
13. P-MAPA and Interleukin-12 Reduce Cell Migration/Invasion and Attenuate the Toll-Like Receptor-Mediated Inflammatory Response in Ovarian Cancer SKOV-3 Cells: A Preliminary Study.
Lupi LA; Delella FK; Cucielo MS; Romagnoli GG; Kaneno R; Nunes IDS; Domeniconi RF; Martinez M; Martinez FE; Fávaro WJ; Chuffa LGA
Molecules; 2019 Dec; 25(1):. PubMed ID: 31861351
[TBL] [Abstract][Full Text] [Related]
14. Preoperative abdominal fat distribution and systemic immune inflammation were associated with response to intravesical Bacillus Calmette-Guerin immunotherapy in patients with non-muscle invasive bladder cancer.
Ke ZB; Chen H; Chen JY; Cai H; Lin YZ; Sun XL; Huang JB; Zheng QS; Wei Y; Xue XY; Xu N
Clin Nutr; 2021 Dec; 40(12):5792-5801. PubMed ID: 34775222
[TBL] [Abstract][Full Text] [Related]
15. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
Huang Z; Liu H; Wang Y; Zhang C; Xu T
Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
[TBL] [Abstract][Full Text] [Related]
16. Electromotive Drug Administration of Mitomycin C (EMDA/MMC) versus Intravesical Immunotherapy with Bacillus Calmette-Guérin (BCG) in Intermediate and High Risk Non Muscle Invasive Bladder Cancer.
Zazzara M; Nazaraj A; Scarcia M; Cardo G; Carando R; Ludovico GM
Urol Int; 2023; 107(1):64-71. PubMed ID: 34933307
[TBL] [Abstract][Full Text] [Related]
17. Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non-muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy.
Mayr R; Eckstein M; Wirtz RM; Santiago-Walker A; Baig M; Sundaram R; Carcione JC; Stoehr R; Hartmann A; Bolenz C; Burger M; Otto W; Erben P; Breyer J
Eur Urol; 2022 Jun; 81(6):606-614. PubMed ID: 35351346
[TBL] [Abstract][Full Text] [Related]
18. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
Arends TJ; Nativ O; Maffezzini M; de Cobelli O; Canepa G; Verweij F; Moskovitz B; van der Heijden AG; Witjes JA
Eur Urol; 2016 Jun; 69(6):1046-52. PubMed ID: 26803476
[TBL] [Abstract][Full Text] [Related]
19. A novel therapeutic strategy for non-muscle invasive bladder cancer: OncoTherad® immunotherapy associated with platelet-rich plasma.
Ribeiro de Souza B; Brum Reis I; Cardoso de Arruda Camargo G; Oliveira G; Cristina Dias Q; Durán N; José Fávaro W
Int Immunopharmacol; 2023 Oct; 123():110723. PubMed ID: 37531827
[TBL] [Abstract][Full Text] [Related]
20. Intravesical Thalidomide boosts bacillus Calmette-Guérin (BCG) in non-muscle invasive bladder cancer treatment.
Passos GR; Camargo JA; Ferrari KL; Saad MJA; de Mattos AC; Reis LO
Med Oncol; 2017 Dec; 35(1):3. PubMed ID: 29209984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
